Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;48(8):2566-2572.
doi: 10.1007/s00259-020-05177-z. Epub 2021 Jan 15.

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Heribert Hänscheid  1 , Philipp E Hartrampf  2 , Andreas Schirbel  2 , Andreas K Buck  2 , Constantin Lapa  2   3
Affiliations

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Heribert Hänscheid et al. Eur J Nucl Med Mol Imaging. 2021 Jul.

Abstract

Purpose: The radiolabelled somatostatin analogue [177Lu]Lu-DOTA-EB-TATE binds to albumin via Evans blue, thereby increasing the residence time in the blood and potentially allowing more therapeutic agent to be absorbed into the target tissue during peptide receptor radionuclide therapy. It was tested in selected patients whether the substance is superior to [177Lu]Lu-DOTA-TOC.

Methods: Activity kinetics in organs and tumours after [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC were compared intraindividually in five patients with progressive somatostatin receptor-positive disease scheduled for radionuclide therapy.

Results: In comparison to [177Lu]Lu-DOTA-TOC, tumour doses per administered activity were higher for [177Lu]Lu-DOTA-EB-TATE in 4 of 5 patients (median ratio: 1.7; range: 0.9 to 3.9), kidney doses (median ratio: 3.2; range: 1.6 to 9.8) as well as spleen doses (median ratio: 4.7; range 1.2 to 6.2) in all patients, and liver doses in 3 of 4 evaluable patients (median ratio: 4.0; range: 0.7 to 4.9). The tumour to critical organs absorbed dose ratios were higher after [177Lu]Lu-DOTA-TOC in 4 of 5 patients.

Conclusions: Prior to a treatment with [177Lu]Lu-DOTA-EB-TATE, it should be assessed individually whether the compound is superior to established substances.

Keywords: Biokinetics; DOTA-EB-TATE; Evans blue; Intraindividual comparison; Somatostatin receptor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Camera images (with regions of interest; background regions not shown) of Patient 1 taken 1 day after administration of a 185 MBq [177Lu]Lu-DOTA-EB-TATE (red) and b 200 MBq [177Lu]Lu-DOTA-TOC (purple). c Measured total body retention and net counts per administered activity (cnts/MBq) in the regions of interest with bi-exponential fit functions. L1 and L2 denote tumour lesions
Fig. 2
Fig. 2
Anterior images of Patient 5 after diagnostics with [68Ga]Ga-DOTA-TOC (left), [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC (center), and therapy with [177Lu]Lu-DOTA-TOC (right). The colour scales of the 177Lu scans are normalised to the activity administered. Tumour to kidneys uptake ratio was identical in both diagnostic assessments with 177Lu but improved by a factor of 2 with arginine/lysine medication in therapy
See this image and copyright information in PMC

References

    1. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(13):2124–2130. doi: 10.1200/JCO.2007.15.2553. - DOI - PubMed
    1. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–2135. doi: 10.1007/s00259-011-1902-1. - DOI - PubMed
    1. Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, et al. The theranostic promise for neuroendocrine tumors in the late 2010s - where do we stand, where do we go? Theranostics. 2018;8(22):6088–6100. doi: 10.7150/thno.30357. - DOI - PMC - PubMed
    1. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(17):2416–2423. doi: 10.1200/jco.2010.33.7873. - DOI - PubMed
    1. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–135. doi: 10.1056/NEJMoa1607427. - DOI - PMC - PubMed

Publication types